Race Oncology Ltd - Asset Resilience Ratio
Race Oncology Ltd (RAC) has an Asset Resilience Ratio of 78.11% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read debt load of Race Oncology Ltd for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2024)
This chart shows how Race Oncology Ltd's Asset Resilience Ratio has changed over time. See Race Oncology Ltd (RAC) net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Race Oncology Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Race Oncology Ltd (RAC) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 0% |
| Short-term Investments | AU$15.80 Million | 78.11% |
| Total Liquid Assets | AU$15.80 Million | 78.11% |
Asset Resilience Insights
- Very High Liquidity: Race Oncology Ltd maintains exceptional liquid asset reserves at 78.11% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Race Oncology Ltd Industry Peers by Asset Resilience Ratio
Compare Race Oncology Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Ascendis Pharma AS
F:A71 |
Biotechnology | 0.00% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076 |
Biotechnology | 1.39% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333 |
Biotechnology | 35.96% |
|
Shanghai Shen Lian Biomedical Corp
SHG:688098 |
Biotechnology | 3.87% |
Annual Asset Resilience Ratio for Race Oncology Ltd (2011–2024)
The table below shows the annual Asset Resilience Ratio data for Race Oncology Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-06-30 | 78.11% | AU$15.80 Million ≈ $11.18 Million |
AU$20.23 Million ≈ $14.31 Million |
+4.53pp |
| 2023-06-30 | 73.58% | AU$19.60 Million ≈ $13.87 Million |
AU$26.64 Million ≈ $18.85 Million |
+0.29pp |
| 2022-06-30 | 73.28% | AU$27.50 Million ≈ $19.46 Million |
AU$37.52 Million ≈ $26.55 Million |
-- |
| 2017-06-30 | 0.00% | AU$0.00 ≈ $0.00 |
AU$6.00 Million ≈ $4.25 Million |
-- |
| 2013-12-31 | 3.45% | AU$9.99 Million ≈ $7.07 Million |
AU$289.97 Million ≈ $205.18 Million |
+0.67pp |
| 2012-12-31 | 2.77% | AU$10.00 Million ≈ $7.08 Million |
AU$360.83 Million ≈ $255.31 Million |
-11.31pp |
| 2012-06-30 | 14.09% | AU$60.00 Million ≈ $42.45 Million |
AU$425.96 Million ≈ $301.39 Million |
+5.95pp |
| 2011-06-30 | 8.13% | AU$30.92 Million ≈ $21.88 Million |
AU$380.25 Million ≈ $269.05 Million |
-- |
About Race Oncology Ltd
Racura Oncology Ltd operates as a Phase 3 clinical biopharmaceutical company for cancer care. Its lead asset is RCDS1 (E,E-bisantrene), a small molecule anticancer agent that primarily functions through G4-DNA & RNA binding to potent inhibition of the cancer growth regulator MYC. The company is advancing a proprietary formulation of RCDS1 (RC220) to address the unmet needs of patients across vari… Read more